Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
"The FDA's approval of Imdelltra marks a pivotal moment for patients battling [extensive-stage small cell lung cancer]," Dr.
(Reuters) - The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted ...
The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
Results from a mid-stage trial , opens new tab ... drugs. Amgen said it will need to complete its larger, pivotal trial in advanced small cell lung cancer to receive full FDA approval of the ...
The US FDA has approved Amgen's Bkemv as an interchangeable biosimilar to Soliris for the treatment of specific rare diseases ...
The FDA approved Imdelltra more than three weeks ahead of its deadline, and based its decision on a trial showing the drug shrank tumors in 40% of patients who received it. Amgen will need to complete ...
The Food and Drug Administration on Thursday granted accelerated approval to a new dual-acting drug from Amgen to treat small ... antibody to gain FDA approval in cancer, and the first in small ...
"The FDA's approval of ... chief scientific officer at drug maker Amgen, said in a company news release. "Imdelltra offers these patients who are in urgent need of new innovative therapies hope ...
The Food and Drug ... made by Amgen to treat the most deadly form of lung cancer. The drug, called Imdelltra, can be used for patients with advanced small-cell lung cancer if another treatment ...